The Biotechnology Industry Organization, the industry's advocate group, said the bill strikes the right balance between innovation and balance. The Eshoo-Barton-Inslee bill "provides patients with the right balance between innovation and competition," said Jim Greenwood, president of the biotechnology industry group, in a statement.
Biologics are complex and expensive medicines derived from proteins manufactured in living cells. Traditional drugs are made by mixing chemicals.
La ley dará a los biogenéricos 14 años de protección antes de que puedan entrar los genéricos en el mercado. Obviamente, la reacción de estos no se hizo esperar...Debra Barrett, senior vice president of government affairs de Teva, declaró:
“is clearly written to protect brand-name drugs and their innovators’ government-granted monopoly at the expense of access and innovation. This bill will dampen innovation and deny Americans access to more affordable healthcare”.
Tambien reaccionó la Generic Pharmaceutical Association (GPhA), con otro proyecto de ley: Promoting Innovation and Access to Life-Saving Medicine Act donde se proponen solo cinco años de exclusividad...
Mas...
Entradas
No hay comentarios:
Publicar un comentario